---
schema_version: "secwatch.filing_event.v1"
accession: "0001639691-24-000054"
form_type: "8-K"
ticker: "LIVN"
cik: "0001639691"
company_name: "LivaNova PLC"
filed_at: "2024-05-01T23:59:59+00:00"
generated_at: "2026-06-03T02:56:05.423747+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# LivaNova Q1 revenue $294.9M (+12% YoY); raises FY2024 guidance; OSPREY study positive

## Summary
- Q1 revenue $294.9M, up 12.0% reported, 12.4% constant-currency YoY; adjusted EPS $0.73 vs GAAP loss $0.78.
- Cardiopulmonary and Neuromodulation each grew double-digit; ACS wind down on track for end-2024.
- Raised full-year 2024 revenue and adjusted diluted EPS guidance (exact figures not in excerpt).
- Positive predictive outcome in OSPREY obstructive sleep apnea study; enrollment completed.
- Closed $345M 2.50% convertible notes due 2029; repurchased $230M exchangeable notes due 2025.

## SEC filing metadata
- accession: 0001639691-24-000054
- form_type: 8-K
- ticker: LIVN
- cik: 0001639691
- company_name: LivaNova PLC
- filed_at: 2024-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1639691/000163969124000054/0001639691-24-000054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1639691/000163969124000054/livn-20240501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001639691-24-000054
- JSON: https://secwatch.observer/filing/0001639691-24-000054.json
- Plain text: https://secwatch.observer/filing/0001639691-24-000054.txt

## Key facts
- Earnings Releases
  LivaNova PLC reported quarter ended March 31, 2024 results: revenue $294.9 million. Guidance raised.
  - Period: quarter ended March 31, 2024
  - Revenue: $294.9 million
  - Guidance: raised
  - Result: reported results
  source text: quarter ended March 31, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance. Financial Summary and Highlights (1) • First-quarter revenue of $294.9 million increased 12.0% on a reported basis and 12.4% on a constant-currency basis, as compared to the prior-year period. Excluding the impact of the Advanced Circulatory Support (ACS)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1639691/000163969124000054/0001639691-24-000054-index.htm
- Earnings Releases
  LivaNova PLC reported first quarter 2024 results: EPS First-quarter U.S. GAAP diluted loss per share was $0.78 and adjusted diluted earnings per share was $0.73.
  - Period: first quarter 2024
  - EPS: First-quarter U.S. GAAP diluted loss per share was $0.78 and adjusted diluted earnings per share was $0.73
  - Result: reported results
  source text: First-quarter U.S. GAAP diluted loss per share was $0.78 and adjusted diluted earnings per share was $0.73
  evidence_url: https://www.sec.gov/Archives/edgar/data/1639691/000163969124000054/0001639691-24-000054-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.